Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 6/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PPIA | P62937 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1282700 | 0.89 | CYP3A4 (0.37) | CYP3A4GPR119MAPTRETPPIA | |
| SCHEMBL16909354 | 0.87 | CYP3A4 (0.36) | CYP3A4GPR119MAPTRETPPIA | |
| SCHEMBL15416347 | 0.85 | CYP3A4 (0.40) | CYP3A4GPR119RETPPIA | |
| SCHEMBL3215428 | 0.78 | DRD2 (0.41) | PPIAPIK3CDPIK3C2B | |
| SCHEMBL1282440 | 0.78 | PANK3 (0.39) | CYP3A4PTPN11GPR119MAPTRET | |
| SCHEMBL28713485 | 0.77 | RET (0.41) | RET | |
| SCHEMBL15539980 | 0.76 | GPR119 (0.34) | CYP3A4PTPN11GPR119MAPTRET | |
| SCHEMBL3489842 | 0.76 | PAK1 (0.46) | MAPT | |
| SCHEMBL3491122 | 0.75 | JAK3 (0.40) | MAPTPPIA | |
| SCHEMBL28719905 | 0.75 | RET (0.42) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070747-A1 | 2(1H)-QUINOLINONE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2021-03-11 | — | — | US | disclosed |
| EP-3604281-A1 | 2(1H)-QUINOLINONE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070747-A1 | 2(1H)-QUINOLINONE DERIVATIVE | TOP2A, TOP2B, TOP1 | CYP3A4 233/4885PTPN11 4371/4885GPR119 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.